Search Results

Yield10 Bioscience, Inc. announced that USDA-APHIS’s Biotechnology Regulatory Services has determined that Yield10’s Camelina sativa varieties developed using genetic engineering to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States.

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that USDA-APHIS’s Biotechnology Regulatory Services has determined that Yield10’s glufosinate tolerant Camelina sativa may be grown and bred in the United States.

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, announced the U.S. Department of Agriculture approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza.

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that the U.S. Department of Agriculture Animal & Plant Health Inspection Service’s Biotechnology Regulatory Services has determined that Yield10’s stacked herbicide tolerant Camelina sativa may be grown and bred in the United States.

bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the incorporation of the company’s GENE-UP® CAMPYLOBACTER assay into the methodology used by the USDA-FSIS Field Service Laboratories.

The U.S. Food and Drug Administration announced the signing of a formal agreement with the U.S. Department of Agriculture and the U.S. Environmental Protection Agency to renew their Federal Interagency Collaboration to Reduce Food Loss and Waste.

In response to President Biden’s Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration, and the U.S. Department of Agriculture have developed a plan to update, streamline, and clarify their regulations and oversight mechanisms for products of biotechnology.

Plus Therapeutics, Inc. today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).

Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix.

Telix Pharmaceuticals Limited announces that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its American Depository Shares, representing the Company’s ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nasdaq Global Market under the symbol “TLX”.